Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amgen Inc announces pivotal study positive results


Monday, 7 Apr 2014 08:00am EDT 

Amgen Inc:New detailed data from two Phase 3 pivotal studies regarding patients with high cholesterol who cannot tolerate statins (GAUSS-2) and patients undergoing statin therapy with high cholesterol (LAPLACE-2).Stating that treatment using novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in significant reduction in low-density lipoprotein cholesterol (LDL-C) between 37-39 pct.Achieved 55-76 pct compared to placebo when used in combination with patients belonging to LAPLACE-2. 

Company Quote

122.01
0.9 +0.74%
23 Jul 2014